metformin has been researched along with Diseases, Metabolic in 43 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to determine whether metformin promotes weight loss in overweight outpatients with chronic schizophrenia or schizoaffective disorder." | 9.17 | Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. ( Catellier, DJ; Golden, LH; Hamer, RM; Jarskog, LF; Lavange, L; Lieberman, JA; Ray, N; Stewart, DD; Stroup, TS, 2013) |
| "This meta-analysis examined the effectiveness and safety of metformin to prevent or treat weight gain and metabolic abnormalities associated with antipsychotic drugs." | 8.91 | Metformin for Weight Gain and Metabolic Abnormalities Associated With Antipsychotic Treatment: Meta-Analysis of Randomized Placebo-Controlled Trials. ( de Leon, J; Li, XB; Tang, YL; Wang, CY; Xiang, YQ; Zheng, W, 2015) |
| "Metformin attenuated the olanzapine- and risperidone-induced metabolic dysfunctions in MK801-induced schizophrenia-like rats without reducing the therapeutic effects of the antipsychotics." | 7.96 | Metformin attenuates antipsychotic-induced metabolic dysfunctions in MK801-induced schizophrenia-like rats. ( Huang, H; Li, X; Liu, Y; Liu, Z; Luo, C; Mao, X; Wang, X; Zhao, J; Zhou, H, 2020) |
| "Metformin and placebo were administered orally for 12 weeks in escalating doses: 850 mg/day for the first 5 days, 850 mg twice a day for the next 5 days, and 850 mg three times a day subsequently." | 6.94 | Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial. ( Ajjan, R; Ajodha, S; Akanle, O; Bestwick, JP; Christ-Crain, M; Fraser, W; Gabrovska, P; Grossman, AB; Kelly, S; Kola, B; Korbonits, M; Pernicova, I; Pitzalis, C; Sahdev, A; Stadler, M, 2020) |
| "Metformin has been widely used as a first-line anti-diabetic medicine for the treatment of type 2 diabetes (T2D)." | 6.52 | Metformin and metabolic diseases: a focus on hepatic aspects. ( Botchlett, R; Chen, L; Hu, X; Huo, Y; Woo, SL; Wu, C; Zheng, J, 2015) |
| "Metformin has been introduced as a therapeutic option in PCOS, targeting of cardiometabolic and reproductive abnormalities on the basis of its action on the reduction of glucose levels and the attenuation of insulin resistance." | 6.46 | Metformin in polycystic ovary syndrome. ( Christakou, C; Diamanti-Kandarakis, E; Economou, F; Palimeri, S, 2010) |
| "The purpose of this study was to determine whether metformin promotes weight loss in overweight outpatients with chronic schizophrenia or schizoaffective disorder." | 5.17 | Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. ( Catellier, DJ; Golden, LH; Hamer, RM; Jarskog, LF; Lavange, L; Lieberman, JA; Ray, N; Stewart, DD; Stroup, TS, 2013) |
| "The role of leptin in atypical antipsychotic-induced metabolic dysfunction was explored by assessing the anthropometric and metabolic profile and the response to metformin (MET) of clozapine- (CLZ) treated schizophrenia patients according to their single nucleotide polymorphisms (SNPs) in the leptin promoter (LEP2548/GA) and leptin receptor (LEPR Q223R) genes." | 5.14 | Polymorphisms of the LEP- and LEPR genes, metabolic profile after prolonged clozapine administration and response to the antidiabetic metformin. ( Baptista, T; Carrizo, E; Connell, L; de Baptista, EA; Fernández, E; Fernández, I; Fernández, V; Mogollón, J; Prieto, D; Sandia, I; Valbuena, D, 2010) |
| "The second generation antipsychotic drugs, such as risperidone, olanzapine, and quetiapine, are effective in treating patients with schizophrenia and have been considered as the first line therapy." | 5.13 | Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine. ( Chen, CH; Chiu, CC; Huang, MC; Liu, HC; Lu, ML; Wu, TH, 2008) |
| " An association between metabolic syndrome, inflammatory cytokinesand incidence of MM has been also described, while the use of metformin and statins has been identified as a positive prognostic factor for the disease course." | 5.12 | Metabolic Disorders in Multiple Myeloma. ( Dimopoulos, MA; Gavriatopoulou, M; Ntanasis-Stathopoulos, I; Paschou, SA, 2021) |
| "This meta-analysis examined the effectiveness and safety of metformin to prevent or treat weight gain and metabolic abnormalities associated with antipsychotic drugs." | 4.91 | Metformin for Weight Gain and Metabolic Abnormalities Associated With Antipsychotic Treatment: Meta-Analysis of Randomized Placebo-Controlled Trials. ( de Leon, J; Li, XB; Tang, YL; Wang, CY; Xiang, YQ; Zheng, W, 2015) |
| "Olanzapine treatment increased the body weight, blood glucose and triglyceride levels, and the number of adipocytes in the liver." | 4.02 | Coadministration of metformin prevents olanzapine-induced metabolic dysfunction and regulates the gut-liver axis in rats. ( Huang, HX; Liu, ZQ; Luo, C; Mao, XY; Wang, X; Zhou, HH, 2021) |
| " Berberine, which is a modulator of TRPV1, has proven antiobesity and antidiabetic potentials." | 3.96 | Berberine attenuated olanzapine-induced metabolic alterations in mice: Targeting transient receptor potential vanilloid type 1 and 3 channels. ( Bansal, Y; Bishnoi, M; Kondepudi, KK; Kuhad, A; Medhi, B; Singh, DP; Singh, R; Sodhi, RK, 2020) |
| "Metformin attenuated the olanzapine- and risperidone-induced metabolic dysfunctions in MK801-induced schizophrenia-like rats without reducing the therapeutic effects of the antipsychotics." | 3.96 | Metformin attenuates antipsychotic-induced metabolic dysfunctions in MK801-induced schizophrenia-like rats. ( Huang, H; Li, X; Liu, Y; Liu, Z; Luo, C; Mao, X; Wang, X; Zhao, J; Zhou, H, 2020) |
| "What is the central question of this study? Studies reported the efficacy of metformin as a promising drug for preventing or treating of metabolic diseases." | 3.96 | Early metformin treatment improves pancreatic function and prevents metabolic dysfunction in early overfeeding male rats at adulthood. ( Alves, VS; de Moraes, AMP; de Oliveira, JC; Francisco, FA; Franco, CCDS; Malta, A; Martins, IP; Mathias, PCF; Matiusso, CCI; Miranda, RA; Moreira, VM; Pavanello, A; Prates, KV; Previate, C, 2020) |
| "Metformin and placebo were administered orally for 12 weeks in escalating doses: 850 mg/day for the first 5 days, 850 mg twice a day for the next 5 days, and 850 mg three times a day subsequently." | 2.94 | Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial. ( Ajjan, R; Ajodha, S; Akanle, O; Bestwick, JP; Christ-Crain, M; Fraser, W; Gabrovska, P; Grossman, AB; Kelly, S; Kola, B; Korbonits, M; Pernicova, I; Pitzalis, C; Sahdev, A; Stadler, M, 2020) |
| " GH dosage was increased from 0." | 2.72 | Insulin resistant diabetes mellitus in SHORT syndrome: case report and literature review. ( Fujisawa, Y; Fukami, M; Inoue, T; Kagami, M; Masunaga, Y; Muramatsu, M; Ogata, T; Ono, H; Saitsu, H, 2021) |
| "Insulin resistance is becoming an increasingly studied target for therapy, most evidence stemming from the time-honored metformin use." | 2.66 | Current treatment for polycystic ovary syndrome: focus on adolescence. ( Catellani, C; Cirillo, F; Dauriz, M; Lazzeroni, P; Moghetti, P; Sartori, C; Street, ME, 2020) |
| "Obesity and its comorbidities, such as type 2 diabetes mellitus and cardiovascular disease, constitute growing challenges for public health and economies globally." | 2.61 | Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases. ( Clemmensen, C; DiMarchi, RD; Finan, B; Hofmann, SM; Müller, TD; Tschöp, MH, 2019) |
| "Polycystic ovary syndrome is characterized by an excess in androgen levels, ovarian dysfunction, and polycystic ovarian morphology but is also associated with metabolic dysfunction and risk factors for cardiovascular disease." | 2.53 | Treatment Considerations for the Cardiometabolic Signs of Polycystic Ovary Syndrome: A Review of the Literature Since the 2013 Endocrine Society Clinical Practice Guidelines. ( Fields, EL; Trent, ME, 2016) |
| "Metformin has been widely used as a first-line anti-diabetic medicine for the treatment of type 2 diabetes (T2D)." | 2.52 | Metformin and metabolic diseases: a focus on hepatic aspects. ( Botchlett, R; Chen, L; Hu, X; Huo, Y; Woo, SL; Wu, C; Zheng, J, 2015) |
| "Metformin has been introduced as a therapeutic option in PCOS, targeting of cardiometabolic and reproductive abnormalities on the basis of its action on the reduction of glucose levels and the attenuation of insulin resistance." | 2.46 | Metformin in polycystic ovary syndrome. ( Christakou, C; Diamanti-Kandarakis, E; Economou, F; Palimeri, S, 2010) |
| "Metformin was used as a positive control." | 1.51 | Human adipose tissue mesenchymal stem cells as a novel treatment modality for correcting obesity induced metabolic dysregulation. ( Bhonde, RR; Datta, I; Shree, N; Venkategowda, S; Venkatranganna, MV, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.33) | 18.2507 |
| 2000's | 3 (6.98) | 29.6817 |
| 2010's | 25 (58.14) | 24.3611 |
| 2020's | 14 (32.56) | 2.80 |
| Authors | Studies |
|---|---|
| Rana, S | 1 |
| Blowers, EC | 1 |
| Natarajan, A | 1 |
| Rao, Y | 1 |
| Xu, Z | 1 |
| Hu, YT | 1 |
| Li, C | 1 |
| Xu, YH | 1 |
| Song, QQ | 1 |
| Yu, H | 1 |
| Song, BB | 1 |
| Chen, SB | 1 |
| Li, QJ | 1 |
| Huang, SL | 1 |
| Tan, JH | 1 |
| Ou, TM | 1 |
| Wang, HG | 1 |
| Zhong, GP | 1 |
| Ye, JM | 1 |
| Huang, ZS | 1 |
| Gavriatopoulou, M | 1 |
| Paschou, SA | 1 |
| Ntanasis-Stathopoulos, I | 1 |
| Dimopoulos, MA | 1 |
| Hong, MK | 1 |
| Han, Y | 1 |
| Park, HJ | 1 |
| Shin, MR | 1 |
| Roh, SS | 1 |
| Kwon, EY | 1 |
| Shree, N | 1 |
| Venkategowda, S | 1 |
| Venkatranganna, MV | 1 |
| Datta, I | 1 |
| Bhonde, RR | 1 |
| Zhang, WS | 1 |
| Pan, A | 1 |
| Zhang, X | 1 |
| Ying, A | 1 |
| Ma, G | 1 |
| Liu, BL | 1 |
| Qi, LW | 1 |
| Liu, Q | 1 |
| Li, P | 1 |
| Singh, R | 1 |
| Bansal, Y | 1 |
| Sodhi, RK | 1 |
| Singh, DP | 1 |
| Bishnoi, M | 1 |
| Kondepudi, KK | 1 |
| Medhi, B | 1 |
| Kuhad, A | 1 |
| Pernicova, I | 1 |
| Kelly, S | 1 |
| Ajodha, S | 1 |
| Sahdev, A | 1 |
| Bestwick, JP | 1 |
| Gabrovska, P | 1 |
| Akanle, O | 1 |
| Ajjan, R | 1 |
| Kola, B | 1 |
| Stadler, M | 1 |
| Fraser, W | 1 |
| Christ-Crain, M | 1 |
| Grossman, AB | 1 |
| Pitzalis, C | 1 |
| Korbonits, M | 1 |
| Street, ME | 1 |
| Cirillo, F | 1 |
| Catellani, C | 1 |
| Dauriz, M | 1 |
| Lazzeroni, P | 1 |
| Sartori, C | 1 |
| Moghetti, P | 1 |
| Luo, C | 2 |
| Wang, X | 2 |
| Mao, X | 1 |
| Huang, H | 1 |
| Liu, Y | 1 |
| Zhao, J | 1 |
| Zhou, H | 1 |
| Liu, Z | 1 |
| Li, X | 1 |
| Zhang, Y | 2 |
| Ji, B | 1 |
| Li, J | 1 |
| Li, Y | 1 |
| Zhang, M | 2 |
| Ban, B | 1 |
| De Diego, MV | 1 |
| Gómez-Pardo, O | 1 |
| Groar, JK | 1 |
| López-Escobar, A | 1 |
| Martín-Estal, I | 1 |
| Castilla-Cortázar, I | 1 |
| Rodríguez-Zambrano, MÁ | 1 |
| Masunaga, Y | 1 |
| Fujisawa, Y | 1 |
| Muramatsu, M | 1 |
| Ono, H | 1 |
| Inoue, T | 1 |
| Fukami, M | 1 |
| Kagami, M | 1 |
| Saitsu, H | 1 |
| Ogata, T | 1 |
| Ansari, A | 1 |
| Bose, S | 1 |
| Lim, SK | 1 |
| Wang, JH | 1 |
| Choi, YH | 1 |
| Kim, H | 1 |
| Previate, C | 1 |
| Malta, A | 1 |
| Miranda, RA | 1 |
| Martins, IP | 1 |
| Pavanello, A | 1 |
| de Oliveira, JC | 1 |
| Prates, KV | 1 |
| Alves, VS | 1 |
| Francisco, FA | 1 |
| Moreira, VM | 1 |
| Matiusso, CCI | 1 |
| de Moraes, AMP | 1 |
| Mathias, PCF | 1 |
| Franco, CCDS | 1 |
| Huang, HX | 1 |
| Mao, XY | 1 |
| Zhou, HH | 1 |
| Liu, ZQ | 1 |
| Wang, D | 1 |
| Day, EA | 1 |
| Townsend, LK | 1 |
| Djordjevic, D | 1 |
| Jørgensen, SB | 1 |
| Steinberg, GR | 1 |
| Morgante, G | 1 |
| Massaro, MG | 1 |
| Di Sabatino, A | 1 |
| Cappelli, V | 1 |
| De Leo, V | 1 |
| Nafisa, A | 1 |
| Gray, SG | 1 |
| Cao, Y | 1 |
| Wang, T | 1 |
| Xu, S | 1 |
| Wattoo, FH | 1 |
| Barras, M | 1 |
| Cohen, N | 1 |
| Kamato, D | 1 |
| Little, PJ | 1 |
| Yang, P | 1 |
| Liu, X | 1 |
| Gao, J | 1 |
| Qu, S | 1 |
| Miyamoto, L | 1 |
| Clemmensen, C | 1 |
| Finan, B | 1 |
| Müller, TD | 1 |
| DiMarchi, RD | 1 |
| Tschöp, MH | 1 |
| Hofmann, SM | 1 |
| Park, J | 1 |
| Joe, Y | 1 |
| Ryter, SW | 1 |
| Surh, YJ | 1 |
| Chung, HT | 1 |
| Jarskog, LF | 2 |
| Hamer, RM | 1 |
| Catellier, DJ | 1 |
| Stewart, DD | 1 |
| Lavange, L | 1 |
| Ray, N | 1 |
| Golden, LH | 1 |
| Lieberman, JA | 1 |
| Stroup, TS | 2 |
| Correll, CU | 1 |
| Sikich, L | 1 |
| Reeves, G | 1 |
| Riddle, M | 1 |
| Rosenfeld, JE | 1 |
| Tek, C | 1 |
| Chwastiak, L | 1 |
| Burkewitz, K | 1 |
| Mair, WB | 1 |
| Zheng, J | 1 |
| Woo, SL | 1 |
| Hu, X | 1 |
| Botchlett, R | 1 |
| Chen, L | 1 |
| Huo, Y | 1 |
| Wu, C | 1 |
| Chen, PY | 1 |
| Lu, ML | 2 |
| Huang, MC | 2 |
| Kao, CF | 1 |
| Kuo, PH | 1 |
| Chiu, CC | 2 |
| Lin, SK | 1 |
| Chen, CH | 2 |
| Zheng, W | 1 |
| Li, XB | 1 |
| Tang, YL | 1 |
| Xiang, YQ | 1 |
| Wang, CY | 1 |
| de Leon, J | 1 |
| Fields, EL | 1 |
| Trent, ME | 1 |
| Zhao, H | 1 |
| Bao, WF | 1 |
| Zhang, T | 1 |
| Fernández, E | 2 |
| Carrizo, E | 2 |
| Fernández, V | 1 |
| Connell, L | 2 |
| Sandia, I | 1 |
| Prieto, D | 1 |
| Mogollón, J | 1 |
| Valbuena, D | 1 |
| Fernández, I | 1 |
| de Baptista, EA | 1 |
| Baptista, T | 2 |
| Diamanti-Kandarakis, E | 1 |
| Economou, F | 1 |
| Palimeri, S | 1 |
| Christakou, C | 1 |
| Jansen, HJ | 1 |
| Vervoort, G | 1 |
| van der Graaf, M | 1 |
| Tack, CJ | 1 |
| Hardie, DG | 1 |
| Farese, RV | 1 |
| Sajan, MP | 1 |
| Wu, TH | 1 |
| Liu, HC | 1 |
| Minchoff, LE | 1 |
| Grandin, JA | 1 |
| Currier, JS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevention of Metabolic Complications of Glucocorticoid Excess - a Randomised, Doubleblind,Placebo Controlled Study[NCT01319994] | Phase 2/Phase 3 | 57 participants (Actual) | Interventional | 2012-07-31 | Completed | ||
| Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (METS) - Pilot Study[NCT00816907] | Phase 4 | 146 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Metformin and Lorcaserin for Weight Loss in Schizophrenia[NCT02796144] | Phase 4 | 71 participants (Actual) | Interventional | 2016-09-30 | Terminated (stopped due to The FDA advised of a possible health risk associated with lorcaserin and the drug is being withdrawn.) | ||
| Efficacy and Safety of Add-on Topiramate vs Metformin on Cardio-Metabolic Profile in Patients With Schizophrenia on Atypical Antipsychotics With Metabolic Syndrome: a Randomized Controlled Trial[NCT05663749] | Phase 4 | 60 participants (Actual) | Interventional | 2022-09-20 | Completed | ||
| A Multicenter, Prospective, Randomized Study to Assess the Effect of Metformin Supplementation on IVF Outcome and Intrafollicular Environment in Patients With Polycystic Ovarian Syndrome Undergoing In Vitro Fertilization/Embryo Transfer[NCT03086005] | Phase 3 | 24 participants (Actual) | Interventional | 2011-10-12 | Completed | ||
| A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of a Weight Management Program on Body Weight in Individuals Who Are Overweight and Otherwise Healthy[NCT04107155] | 54 participants (Actual) | Interventional | 2019-07-23 | Completed | |||
| A Randomized Controlled Trial to Evaluate the Effects of Repeated Periods of Modified Fasting to Support Healthy Natural Weight Management and Prevention of Weight Gain in Overweight But Generally Healthy Adults Over the Winter Holiday Period[NCT03372109] | 23 participants (Actual) | Interventional | 2017-11-14 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
change in visceral/subcutaneous fat (NCT01319994)
Timeframe: 3 months minus baseline
| Intervention | ratio (Mean) |
|---|---|
| Metformin | 0.08 |
| Placebo | -0.03 |
The homeostatic model assessment (HOMA) is a method used to quantify insulin resistance and beta (β)-cell function. HOMA2-IR is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin resistance which is the reciprocal of insulin sensitivity (%S)(100/%S) as a percentage of a normal reference population (normal young adults). HOMA2-IR is calculated using the HOMA model: www.dtu.ox.ac.uk/homacalculator/ (NCT01319994)
Timeframe: 3 months minus baseline
| Intervention | HOMA score (Mean) |
|---|---|
| Metformin | 0.22 |
| Placebo | 2.35 |
fasting blood glucose (NCT00816907)
Timeframe: 16 weeks
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | -1.6 |
| Metformin | -2.3 |
Fasting insulin (NCT00816907)
Timeframe: 16 weeks
| Intervention | mU/L (Mean) |
|---|---|
| Placebo | 5.5 |
| Metformin | 1.6 |
high-density lipoprotein (NCT00816907)
Timeframe: 16 weeks
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | -0.4 |
| Metformin | -0.6 |
glycosylated hemoglobin (NCT00816907)
Timeframe: 16 weeks
| Intervention | percent (Least Squares Mean) |
|---|---|
| Placebo | 0.01 |
| Metformin | -0.06 |
low-density lipoprotein (NCT00816907)
Timeframe: 16 weeks
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | -2.0 |
| Metformin | -7.1 |
Total cholesterol (NCT00816907)
Timeframe: 16 weeks
| Intervention | mg/dL (Mean) |
|---|---|
| Placebo | 0.2 |
| Metformin | -8.9 |
serum triglycerides (NCT00816907)
Timeframe: 16 weeks
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | 13.2 |
| Metformin | -7.0 |
Mean difference in body weight change between participants assigned to metformin and participants assigned to placebo from baseline to last study visit (up to 16 weeks) (NCT00816907)
Timeframe: Measured at the last study visit
| Intervention | kilograms (Mean) |
|---|---|
| Placebo | -1.0 |
| Metformin | -3.0 |
Change in body weight in participants assigned to lorcaserin monotherapy treatment and participants assigned to placebo from baseline to last study visit (up to 52 weeks) (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | pounds (Mean) |
|---|---|
| Lorcaserin | -5.18 |
| Placebo | -3.02 |
Change in body weight in participants assigned to lorcaserin/metformin combination treatment and participants assigned to placebo from baseline to last study visit (up to 52 weeks) (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | pounds (Mean) |
|---|---|
| Lorcaserin and Metformin | -13.05 |
| Placebo | -3.02 |
fasting blood glucose (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | -4.30 |
| Lorcaserin | -3.27 |
| Placebo | 3.53 |
high-density lipoprotein (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | 3.8 |
| Lorcaserin | 1.45 |
| Placebo | -0.78 |
glycosylated hemoglobin (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | percentage of glycosylated hemoglobin (Mean) |
|---|---|
| Lorcaserin and Metformin | -0.03 |
| Lorcaserin | 0.07 |
| Placebo | 0.05 |
low-density lipoprotein (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | -7.60 |
| Lorcaserin | -10.86 |
| Placebo | -6.83 |
Total Cholesterol (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | -9.05 |
| Lorcaserin | -13.45 |
| Placebo | -9.21 |
serum triglycerides (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | -18.60 |
| Lorcaserin | -19.68 |
| Placebo | -3.11 |
19 reviews available for metformin and Diseases, Metabolic
| Article | Year |
|---|---|
Small molecule adenosine 5'-monophosphate activated protein kinase (AMPK) modulators and human diseases.
Topics: Adenine Nucleotides; Allosteric Regulation; AMP-Activated Protein Kinases; Humans; Intracellular Sig | 2015 |
Metabolic Disorders in Multiple Myeloma.
Topics: Cell Proliferation; Cytokines; Energy Metabolism; Glycolysis; Humans; Metabolic Diseases; Metabolic | 2021 |
Current treatment for polycystic ovary syndrome: focus on adolescence.
Topics: Adolescent; Contraceptives, Oral, Hormonal; Female; Gene-Environment Interaction; Humans; Hypoglycem | 2020 |
SHORT syndrome in two Chinese girls: A case report and review of the literature.
Topics: Adolescent; Class Ia Phosphatidylinositol 3-Kinase; Female; Growth Disorders; Heterozygote; Humans; | 2020 |
Insulin resistant diabetes mellitus in SHORT syndrome: case report and literature review.
Topics: Brazil; Canagliflozin; Child; Diabetes Complications; Diabetes Mellitus; Drug Therapy, Combination; | 2021 |
GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease.
Topics: Animals; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Growth Differentiation Factor 15; Human | 2021 |
Therapeutic approach for metabolic disorders and infertility in women with PCOS.
Topics: Androgen Antagonists; Anovulation; Clomiphene; Contraceptives, Oral, Hormonal; Female; Gonadotropins | 2018 |
Endothelial function and dysfunction: Impact of metformin.
Topics: Animals; Cardiovascular Diseases; Endothelium, Vascular; Humans; Hypoglycemic Agents; Metabolic Dise | 2018 |
[AMPK as a Metabolic Intersection between Diet and Physical Exercise].
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Biphenyl Compounds; Diet; Drug Discovery; | 2018 |
Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases.
Topics: Animals; Body Mass Index; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Com | 2019 |
Similarities and Distinctions in the Effects of Metformin and Carbon Monoxide in Immunometabolism.
Topics: Animals; Carbon Monoxide; Endoplasmic Reticulum Stress; Humans; Immune System; Metabolic Diseases; M | 2019 |
AMPK at the nexus of energetics and aging.
Topics: Aging; AMP-Activated Protein Kinases; Animals; Aspirin; Energy Metabolism; Humans; Metabolic Disease | 2014 |
Metformin and metabolic diseases: a focus on hepatic aspects.
Topics: Humans; Hypoglycemic Agents; Liver; Metabolic Diseases; Metformin | 2015 |
Metformin for Weight Gain and Metabolic Abnormalities Associated With Antipsychotic Treatment: Meta-Analysis of Randomized Placebo-Controlled Trials.
Topics: Antipsychotic Agents; Humans; Hypoglycemic Agents; Metabolic Diseases; Metformin; Randomized Control | 2015 |
Treatment Considerations for the Cardiometabolic Signs of Polycystic Ovary Syndrome: A Review of the Literature Since the 2013 Endocrine Society Clinical Practice Guidelines.
Topics: Adolescent; Adult; Cardiovascular Diseases; Estrogen Replacement Therapy; Exercise Therapy; Female; | 2016 |
Metformin in polycystic ovary syndrome.
Topics: Cardiovascular Diseases; Female; Humans; Hypoglycemic Agents; Infertility, Female; Metabolic Disease | 2010 |
Sensing of energy and nutrients by AMP-activated protein kinase.
Topics: Adenosine Monophosphate; Adenosine Triphosphate; AMP-Activated Protein Kinases; Animals; Energy Meta | 2011 |
Sensing of energy and nutrients by AMP-activated protein kinase.
Topics: Adenosine Monophosphate; Adenosine Triphosphate; AMP-Activated Protein Kinases; Animals; Energy Meta | 2011 |
Sensing of energy and nutrients by AMP-activated protein kinase.
Topics: Adenosine Monophosphate; Adenosine Triphosphate; AMP-Activated Protein Kinases; Animals; Energy Meta | 2011 |
Sensing of energy and nutrients by AMP-activated protein kinase.
Topics: Adenosine Monophosphate; Adenosine Triphosphate; AMP-Activated Protein Kinases; Animals; Energy Meta | 2011 |
Atypical protein kinase C in cardiometabolic abnormalities.
Topics: Animals; Cardiovascular Diseases; Humans; Insulin; Metabolic Diseases; Metformin; Myocardium; Protei | 2012 |
Syndrome X. Recognition and management of this metabolic disorder in primary care.
Topics: Arteriosclerosis; Diabetes Mellitus, Type 2; Humans; Hypertension; Metabolic Diseases; Metformin; Ob | 1996 |
6 trials available for metformin and Diseases, Metabolic
| Article | Year |
|---|---|
Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial.
Topics: Adult; Aged; Autoimmune Diseases; Double-Blind Method; Female; Glucocorticoids; Humans; Hypoglycemic | 2020 |
Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Dose-Response Relationship, Drug; Double-Blind Method; | 2013 |
Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Dose-Response Relationship, Drug; Double-Blind Method; | 2013 |
Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Dose-Response Relationship, Drug; Double-Blind Method; | 2013 |
Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Dose-Response Relationship, Drug; Double-Blind Method; | 2013 |
The Relationships of Obesity-Related Genetic Variants With Metabolic Profiles and Response to Metformin in Clozapine-Treated Patients With Schizophrenia.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aldose-Ketose Isomerases; Alleles; Antipsychotic Agents | 2015 |
[Advantages of Chinese medicine for treatment of blood sugar and lipid metabolic disorders in patients with polycystic ovarian syndrome].
Topics: Adolescent; Adult; Blood Glucose; Cholesterol, HDL; Cyproterone; Drugs, Chinese Herbal; Female; Huma | 2009 |
Polymorphisms of the LEP- and LEPR genes, metabolic profile after prolonged clozapine administration and response to the antidiabetic metformin.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Body Mass Index; Clozapine; Double-Blind Method; Female; | 2010 |
Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Weight; Female; Glucos | 2008 |
18 other studies available for metformin and Diseases, Metabolic
| Article | Year |
|---|---|
Discovery of a promising agent IQZ23 for the treatment of obesity and related metabolic disorders.
Topics: 3T3-L1 Cells; Animals; Anti-Obesity Agents; Cell Differentiation; Cells, Cultured; Cholesterol; Diet | 2020 |
The Synergistic Action of Metformin and
Topics: Animals; Diet, High-Fat; Glycyrrhiza uralensis; Liver; Metabolic Diseases; Metformin; Mice; Mice, In | 2023 |
Human adipose tissue mesenchymal stem cells as a novel treatment modality for correcting obesity induced metabolic dysregulation.
Topics: Adipose Tissue; Animals; Diet, High-Fat; Disease Models, Animal; Humans; Mesenchymal Stem Cell Trans | 2019 |
Inactivation of NF-κB2 (p52) restrains hepatic glucagon response via preserving PDE4B induction.
Topics: Animals; Blood Glucose; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Diet, High-Fat; Di | 2019 |
Berberine attenuated olanzapine-induced metabolic alterations in mice: Targeting transient receptor potential vanilloid type 1 and 3 channels.
Topics: Animals; Antipsychotic Agents; Berberine; Body Temperature; Body Weight; Cytokines; Drinking; Female | 2020 |
Metformin attenuates antipsychotic-induced metabolic dysfunctions in MK801-induced schizophrenia-like rats.
Topics: Animals; Animals, Newborn; Antipsychotic Agents; Dizocilpine Maleate; Dose-Response Relationship, Dr | 2020 |
Metabolic impact of current therapeutic strategies in Polycystic Ovary Syndrome: a preliminary study.
Topics: Adolescent; Adult; Blood Glucose; Contraceptives, Oral, Combined; Female; Glycated Hemoglobin; Human | 2020 |
Combination of
Topics: Animals; Brain; Brain-Derived Neurotrophic Factor; Diet, Carbohydrate Loading; Diet, High-Fat; Disea | 2020 |
Early metformin treatment improves pancreatic function and prevents metabolic dysfunction in early overfeeding male rats at adulthood.
Topics: Adipose Tissue, White; Animals; Animals, Newborn; Blood Glucose; Body Composition; Body Weight; Fema | 2020 |
Coadministration of metformin prevents olanzapine-induced metabolic dysfunction and regulates the gut-liver axis in rats.
Topics: Adjuvants, Pharmaceutic; Animals; Bacteroides; Blood Glucose; Body Weight; Dose-Response Relationshi | 2021 |
Complete androgen insensitivity syndrome in a young woman with metabolic disorder and diabetes: A case report.
Topics: Amenorrhea; Androgen-Insensitivity Syndrome; Diabetes Mellitus; Dyslipidemias; Female; Humans; Hydro | 2018 |
Metformin for antipsychotic-related weight gain and metabolic abnormalities: when, for whom, and for how long?
Topics: Antipsychotic Agents; Female; Humans; Male; Metabolic Diseases; Metformin; Obesity; Psychotic Disord | 2013 |
Metformin and Alzheimer's disease risk.
Topics: Antipsychotic Agents; Female; Humans; Male; Metabolic Diseases; Metformin; Obesity; Psychotic Disord | 2014 |
Response to Rosenfeld.
Topics: Antipsychotic Agents; Female; Humans; Male; Metabolic Diseases; Metformin; Obesity; Psychotic Disord | 2014 |
Metformin for weight loss in schizophrenia: safe but not a panacea.
Topics: Antipsychotic Agents; Female; Humans; Male; Metabolic Diseases; Metformin; Obesity; Psychotic Disord | 2014 |
Pronounced weight gain in insulin-treated patients with type 2 diabetes mellitus is associated with an unfavourable cardiometabolic risk profile.
Topics: Aged; Body Fat Distribution; Body Weight; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes | 2010 |
Pro12Ala polymorphism of the PPAR-γ2 gene, metabolic syndrome and response to metformin in clozapine-treated patients.
Topics: Adult; Aged; Alanine; Antipsychotic Agents; Blood Glucose; Clozapine; Enzyme-Linked Immunosorbent As | 2012 |
How to manage metabolic complications of HIV therapy: what to do while we wait for answers.
Topics: Anabolic Agents; Anti-HIV Agents; Anticholesteremic Agents; Atorvastatin; Exercise Therapy; Gemfibro | 2000 |